Call today to speak with a recovery expert or take our brief self-test.
For years, GLP-1 medications have been used to help manage type 2 diabetes and support weight loss. More recently, researchers have begun exploring another potential benefit: their ability to reduce cravings and influence some of the brain pathways involved in addiction.
While GLP-1 medications are currently being used off label to treat substance use disorders, research suggests they may help reduce alcohol, nicotine and tobacco cravings and support ongoing recovery efforts for some people. With a decade of research and continuing studies, addiction medicine experts have been evaluating how these medications complement evidence-based treatment as part of a comprehensive recovery plan.
At Hazelden Betty Ford Foundation, our physicians are incorporating GLP-1 medications into treatment plans for patients who meet FDA indications, including obesity or overweight status with related health conditions. While these medications are not intended to replace counseling, peer support, behavioral therapies or ongoing recovery planning, they are a tool that's helping reduce cravings, improve health and help people recover with whole-person care.
Medications such as semaglutide and tirzepatide were first introduced to help regulate blood sugar and improve metabolic health in people living with type 2 diabetes. They’ve been safely used for this type of treatment for approximately 20 years.
Many GLP-1 medications are also prescribed for people living with obesity or those who are overweight and have related health conditions.
Both observational studies and clinical trials suggest some people taking GLP-1 medications report fewer cravings and reduced alcohol consumption. Studies are also looking at their potential in relapse prevention.
Although researchers are also studying tobacco, opioid and other substance use disorders, alcohol use disorder has produced the most promising human research to date.
Medications alone do not address the emotional, behavioral, social and lifestyle factors that contribute to addiction. Comprehensive treatment and ongoing recovery support remain essential.
GLP-1 medications are a class of prescription drugs that mimic a naturally occurring hormone called glucagon-like peptide-1 (GLP-1). This hormone helps regulate blood sugar, slows stomach emptying and signals feelings of fullness after eating. As a result, GLP-1 medications are commonly used to help manage type 2 diabetes and support weight loss in people who meet specific medical criteria.
In recent years, medications such as Wegovy®, Ozempic®, Mounjaro® and Zepbound® have gained widespread attention for their effectiveness in weight management. However, researchers have found that these medications have benefits that extend beyond metabolic health, including a role in reducing cravings and substance use behaviors.
GLP-1 medications work by acting on receptors throughout the body, including the digestive system and the brain. They help:
Researchers also believe GLP-1 medications influence brain pathways involved in reward, motivation and craving. This area of study has generated significant interest among addiction medicine experts because many of the same pathways involved in eating behavior are also involved in substance use disorders.
The connection between GLP-1 medications and addiction was discovered unexpectedly.
As GLP-1 medications became more widely used for diabetes and weight management, some patients began reporting effects that had nothing to do with blood sugar or appetite. In addition to eating less, they noticed they were drinking less alcohol, smoking less frequently or experiencing fewer urges to use certain substances. These reports sparked interest among researchers, who began investigating whether GLP-1 medications might influence some of the same brain systems involved in addiction.
Substance use disorders are influenced by many factors, including genetics, environment, mental health and life experiences. They also involve changes in brain circuits that help regulate reward, motivation and decision-making.
When people use alcohol or other substances, these reward pathways can become overstimulated over time. This can increase cravings and make it more difficult to resist urges, even when someone wants to cut back or stop using altogether. For many people, recovery involves learning new ways to manage these cravings while rebuilding healthy habits and routines.
Because GLP-1 medications appear to affect some of these same brain pathways, researchers are exploring whether they could help reduce the intensity of cravings and make recovery efforts more manageable for some individuals.
Although researchers are still studying the exact mechanisms involved, evidence suggests that GLP-1 medications influence dopamine signaling and other neurochemical processes associated with reward and reinforcement. Dopamine is often referred to as the brain's "reward chemical" because it plays a role in motivation and the anticipation of pleasurable experiences.
Some researchers believe GLP-1 medications reduce the appeal of certain rewarding behaviors, including excessive alcohol consumption, in much the same way they can help reduce overeating. Rather than eliminating pleasure or suppressing normal enjoyment, the medications help decrease the intensity of urges that can drive repetitive behaviors.
While research into GLP-1 medications and addiction has been ongoing over the last decade, alcohol use disorder has emerged as the area with the strongest evidence to date. Findings from observational studies, clinical trials and patient reports have encouraged researchers to take a closer look at whether GLP-1 medications could play a role in reducing cravings and supporting recovery.
Researchers are actively studying how GLP-1s fit into addiction treatment. Recent studies have produced encouraging findings, particularly for alcohol use disorder. For example, a 2025 randomized clinical trial published in JAMA Psychiatry found that semaglutide reduced alcohol craving and several measures of alcohol consumption among adults with alcohol use disorder.
Additional research, including a large cohort study of US veterans published in The BMJ, found lower risks of developing substance use disorders among patients taking GLP-1 receptor agonists compared with other diabetes medications. While these results are promising, experts agree that larger studies are still needed before GLP-1 medications can be considered a standard treatment option for addiction.
Many people in recovery describe cravings as more than a physical urge. They often talk about persistent thoughts about drinking, mental negotiations around alcohol or a feeling that alcohol occupies too much space in their minds.
Although "alcohol noise" is not a medical term, it has become a common way patients describe these repetitive thoughts and urges. Some individuals taking GLP-1 medications report that this mental chatter becomes quieter, making it easier to focus on recovery goals and healthy decision-making. Researchers are still working to understand exactly why this occurs, but many believe it may be connected to the medications' effects on reward pathways and craving-related brain activity.
While research into GLP-1 medications and substance use disorders continues to evolve, these medications are already providing important benefits for some patients who qualify under current prescribing guidelines. At Hazelden Betty Ford Foundation, physicians may prescribe GLP-1 medications for patients who meet FDA-approved indications, such as obesity or overweight status with certain related health conditions, while also addressing their substance use disorder as part of a comprehensive treatment plan.
This approach reflects a whole-person view of recovery. Substance use disorders often affect many aspects of physical health, including nutrition, weight, sleep, exercise habits and chronic disease management. By addressing both addiction and overall wellness, treatment can support healthier lifestyle changes that strengthen long-term recovery.
Medical oversight is an important part of this process. Board-certified physicians and addiction treatment professionals can help determine whether a GLP-1 medication is appropriate, monitor progress, manage side effects and coordinate care throughout the recovery journey. When combined with counseling, recovery support, healthy lifestyle practices and ongoing treatment planning, GLP-1 medications may become one more tool to help patients reduce cravings, improve health outcomes and stay engaged in recovery.
As scientists continue to learn more, Hazelden Betty Ford Foundation remains committed to evaluating innovative, evidence-based approaches that can improve patient care. If you or a loved one is seeking treatment for a substance use disorder, our team can help you explore a personalized recovery plan that addresses your physical, emotional and behavioral health needs.
Ready to learn more? Speak with one of our compassionate admissions specialists today or explore our treatment programs to discover how comprehensive, whole-person care can support lasting recovery.
No. GLP-1 medications are currently FDA-approved for type 2 diabetes and certain weight-related conditions, but they are being used off label to treat substance use disorders. Researchers are actively studying whether these medications may help reduce cravings and support recovery, particularly for people living with alcohol use disorder and tobacco and nicotine use disorder.
Additional research is needed, but clinical studies and patient experiences have generated significant interest among addiction medicine experts. Some people taking GLP-1 medications have reported fewer cravings, reduced alcohol consumption and less "alcohol noise," leading researchers and treatment providers to explore how these medications may complement established, evidence-based addiction treatment approaches.
Research suggests they do. Some clinical studies have found that people taking GLP-1 medications reported reduced alcohol cravings and lower levels of alcohol consumption compared to those receiving a placebo. However, larger studies are still needed to confirm these findings and determine who may benefit most.
Researchers believe GLP-1 medications may influence brain pathways involved in reward, motivation and craving. These effects may help explain why some people report less interest in alcohol and fewer substance-related urges while taking the medications. Scientists are still working to better understand exactly how these effects occur.
GLP-1 medications may be prescribed for people who meet current medical criteria, such as having obesity or being overweight with certain related health conditions. Eligibility is determined by a physician based on an individual's overall health, medical history and treatment goals.
No. While GLP-1 medications prove to be a helpful recovery tool for some individuals, they do not address all of the behavioral, emotional and social factors involved in addiction. Comprehensive treatment that may include counseling, peer support, behavioral therapies and medical care remains essential for long-term recovery.
Like any prescription medication, GLP-1 medications require appropriate medical evaluation and monitoring. Addiction medicine professionals can help determine whether a medication is appropriate, manage side effects and ensure it is used as part of a comprehensive treatment plan that supports both recovery and overall health.